Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of January 2019, specifically dated January 18, 2019. The registrant is a foreign private issuer based in Petach-Tikva, Israel, and files annual reports on Form 20-F.
Key Financial Metrics
The filing discloses a specific capital raise event but does not provide comprehensive financial statements for the period.
- Capital Raised: The company entered into a definitive agreement to receive gross proceeds of approximately $2,350,000 from an institutional investor.
- Revenue, Profit, and Margins: The filing text does not provide a clear value for revenue, net income, or operating margins.
- Cash Flow and Liquidity: While the $2,350,000 proceeds will impact liquidity, the filing text does not provide a clear value for total cash balances or operating cash flow.
- Debt: The filing text does not provide a clear value for outstanding debt obligations.
Material Changes
The primary material change reported is the execution of a definitive financing agreement with an institutional investor. No comparative financial data or changes in operational metrics versus prior periods are included in this specific filing.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the financing agreement. The filing incorporates a press release (Exhibit 99.1) by reference but does not contain specific forward-looking guidance, risk factors, or details on contingencies within the body of this document.
Investor Verification Checklist
- Verify the terms of the definitive agreement with the institutional investor referenced in Exhibit 99.1.
- Confirm the closing date and actual receipt of the $2,350,000 gross proceeds.
- Review the attached press release for details on the use of proceeds and any dilution effects.
- Check subsequent filings for updated cash balances and liquidity status post-closing.